

# Curriculum Vitae

## Personal Data

<b>Full Name:</b>	Sook Ryun Park, M.D., Ph.D.		
<b>Position Title:</b>	Assistant Professor		
<b>Address:</b>	Asan Medical Center 88, Olympic-ro, 43-Gil, Songpa-gu, Seoul 05505, Republic of Korea		
<b>Telephone Number:</b>	02-3010-3206		
<b>Fax Number</b>	02-3010-6954		
<b>E-mail</b>	srpark@amc.seoul.kr		
<b>Date</b>		<b>Signature</b>	

## Education

<b>Institution</b>	<b>Location</b>	<b>Degree</b>	<b>Year Conferred</b>	<b>Field of Study</b>
College of Medicine, Seoul National University	Seoul, Republic of Korea	Ph.D.	2009	Internal Medicine
College of Medicine, Seoul National University	Seoul, Republic of Korea	M.M.Sc.	2002	Internal Medicine
College of Medicine, Seoul National University	Seoul, Republic of Korea	M.D.	1998	Medicine

## Training

<b>Title/Type</b>	<b>Specialty</b>	<b>Institution</b>	<b>Location</b>	<b>Start Date (mm/dd/yy)</b>	<b>End Date (mm/dd/yy)</b>
Fellowship	Medical Oncology	Research Institute & Hospital, National Cancer Center	Goyang, Gyeonggi, Republic of Korea	03/01/2004	02/28/2005
Fellowship	Medical Oncology/Hematology	Seoul National University Hospital	Seoul, Republic of Korea	03/01/2003	02/28/2004
Residency	Internal Medicine	Seoul National University Hospital	Seoul, Republic of Korea	03/01/1999	02/28/2003
Internship	Medicine	Seoul National University Hospital	Seoul, Republic of Korea	03/01/1998	02/28/1999

### **Board Certification**

<b>Board</b>	<b>License Number</b>	<b>Date (mm/dd/yy)</b>
Korean Board of Internal Medicine	64953	2/28/2003
Korean Board of Hemato-Oncology	8505	2005

### **Research and Professional Experience**

<b>Position</b>	<b>Institution</b>	<b>Location</b>	<b>Dates of Employment (mm/dd/yy)</b>
Associate Professor	Asan Medical Center	Seoul, Republic of Korea	03/01/2015-present
Member of Institutional Review Board	Asan Medical Center	Seoul, Republic of Korea	01/01/2015-present
Clinical Assistant Professor	Asan Medical Center	Seoul, Republic of Korea	03/01/2013-02/28/2015
Visiting fellow	National Cancer Institute/National Institutes of Health	Bethesda, MD, USA	10/01/2010-9/30/2012
Chief of Ambulatory Treatment Center	Research Institute & Hospital, National Cancer Center	Goyang, Gyeonggi, Republic of Korea	12/01/2007-10/01/2010
Member of Institutional Review Board	Research Institute & Hospital, National Cancer Center	Goyang, Gyeonggi, Republic of Korea	11/01/2009-9/30/2010
Senior Scientist	Division of Translational & Clinical Research I, Research Institute & Hospital, National Cancer Center	Goyang, Gyeonggi, Republic of Korea	02/01/2009-02/28/2013
Associate Scientist	Division of Translational & Clinical Research I, Research Institute & Hospital, National Cancer Center	Goyang, Gyeonggi, Republic of Korea	07/02/2007-01/31/2009
Staff Physician	Research Institute & Hospital, National Cancer Center	Goyang, Gyeonggi, Republic of Korea	03/01/2005-02/28/2013

### **Awards**

May 16, 2014 Korean Association for Clinical Oncology BORYUNG Academic Award
June 13, 2012, the 1 <sup>st</sup> Korean Cancer Association Kwang Dong Academic Award
Dec. 30, 2011 National Cancer Center Research Award

June 16, 2006, the 6th Korean Cancer Association GSK Academic Award
2006 Roche Asia Oncology Forum Award
2006 National Cancer Center SCI Award
2006 National Cancer Center Impact Factor Award
2006 European Society for Medical Oncology, Travel Award
2005 ASCO GI Cancers Symposium, Merit Awards

### **Membership in Professional Societies**

American Society of Clinical Oncology
American Association for Cancer Research
Korean Cancer Association
Korean Association for Clinical Oncology
Korean Society of Hematology
Korean Association of Internal Medicine

### **Publication**

#### **Article**

<b>Corresponding and/or first author</b>
<b>Sook Ryun Park</b> , Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, hang Gok Woo, Hwoon-Yong Jung, Jeong Hoon Lee, Gin Hyug Lee, Yoon-Koo Kang : Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer. 2016 Jan; 53:42–50
<b>Sook Ryun Park</b> . Management of gastric cancer: East vs west. Curr Probl Cancer. 2015 Nov-Dec;39(6):315-41
<b>Park SR</b> , Ryu MH, Ryoo BY, Beck MY, Lee IS, Choi MJ, Lee MW, Kang YK. Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Res Treat. 2015 Sep 1.[Epub ahead of print]
Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, <b>Park SR</b> . A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2015 Apr 8. [Epub ahead of print]
Lim HS, Ryu KW, Lee JH, Kim YW, Ju Choi I, Kim MJ, Park YI, Hwang A, <b>Park SR</b> . Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer. J Clin Pharmacol. 2015 Aug;55(8):926-35
<b>Park SR</b> , Kang YK. Perioperative treatments for resectable gastric cancer. J Korean Med Assoc 2015 March; 58(3): 201-208.

Kim MJ, <b>Park SR</b> . Chemotherapy for Advanced Gastric Cancer in Elderly Patients. Korean J Med. 2014 Nov;87(5):521-529
<b>Park SR</b> , Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH. Validation of a Hypoxia-Inducible Factor-1 $\alpha$ Specimen Collection Procedure and Quantitative ELISA in Solid Tumor Tissues. Anal Biochem. 2014 Aug 15;459:1-11
Lee KW, <b>Park SR</b> , Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, Bang YJ. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Invest New Drugs. 2013 Dec;31(6):1547-58
<b>Park SR</b> , Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64
<b>Park SR</b> , Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol. 2013;71(4):981-90
<b>Park SR</b> , Davis-Millin M, Doroshow JH, Kummar S. Safety and feasibility of combinations of targeted agents in solid tumors. Nat Rev Clin Oncol. 2013 Jan 29;10(3):154-68.
<b>Park SR</b> , Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am. 2012; 26(3):649-70, ix.
<b>Park SR</b> , Kong S-Y, Nam B-H, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW Kim, Ryu KW, Lee JH, Rhee J, Park Y-I, Kim NK. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer 2011; 104(7):1126-34.
<b>Park SR</b> , Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol. 2011;22(4):890-6.
Park IH, Kim SY, Kim YW, Ryu KW, Lee JH, Park YI, Kim NK, <b>Park SR</b> . Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 2011; 67(1):127-36.
Kang MH, Kim SN, Kim NK, Park YI, Kim YW, Ryu KW, Lee JH, Lee JS, <b>Park SR</b> . Clinical Outcomes and Prognostic Factors of Metastatic Gastric Carcinoma Patients Who Experience Gastrointestinal Perforation During Palliative Chemotherapy. Ann Surg Oncol. 2010;17(12):3163-72.
<b>Park SR</b> , Kim MJ, Ryu KW, Lee JH, Lee JS, Nam BH, Choi IJ, Kim WY. Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: A viewpoint in the era of preoperative treatment. Ann Surg.2010;251(3):428-35
<b>Park SR</b> , Cho HJ, Moon KJ, Chun KH, Kong SY, Yoon SS, Lee JS, Park S. Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60. Leuk Lymphoma 2010;51:132-45
<b>Park SR</b> , Kook MC, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Lee JS, Park YI, Kim NK. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010;65(3):579-87

Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, <b>Park SR</b> . Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. <i>Pharmacogenomics</i> 2009;10:1147-55
<b>Park SR</b> , Lee JS, Kim CG, Kim HK, Kook MC, Kim YW, Ryu KW, Lee JH, Bae JM, Choi IJ. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. <i>Cancer</i> 2008;112(11):2368-76
<b>Park SR</b> , Kim HK, Kim CG, Choi IJ, Lee JS, Lee JH, Ryu KW, Kim YW, Bae JM, Kim NK. Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. <i>Br J Cancer</i> 2008 22;98(8):1305-11.
Han HS, <b>Park SR</b> , Kim SY, Park YI, Lee JS, Kook MC, Choi IJ, Kim CG, Lee JR, Cho SJ, Kim NK. Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer. <i>J Clin Oncol</i> 2008;26:1006-8
<b>Park SR</b> , Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ, Kim CG, Lee JS, Kim YW, Bae JM, Kim HK. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. <i>Br J Cancer</i> 2006;94:1402-1406
<b>Park SR</b> , Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS. Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. <i>J Korean Med Sci.</i> 2006;21:633-638
<b>Park SR</b> , Il Ju Choi, Chan Gyoo Kim, Young-Woo Kim, Keun Won Ryu, Jun Ho Lee, Jong Seok Lee, Jae-Moon Bae, Hark Kyun Kim. Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer. <i>J Gastroenterol</i> 2006;41:339-346
<b>Park SR</b> , Chun JH, Kim Y, Lee JH, Choi IJ, Kim CG, Lee JS, Bae JM, Kim HK. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. <i>Am J Clin Oncol</i> 2005;28:433-438
<b>Park SR</b> , Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK, HK Kim. A multi-center, late phase II clinical trial of genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. <i>Oncol Rep</i> 2004;12:1059-1064
<b>Park SR</b> , Kim JH, Kim do Y, Lee S, Lee SY, Choi IS, Yoon SS, Park S, Kim BG, Kim NK. Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors. <i>Korean J Intern Med</i> 2003;18:21-28
<b>Coauthor</b>
Yoon S, Yoo C, Ryu MH, Kang MJ, Ryoo BY, <b>Park SR</b> , Yook JH, Oh ST, Yoo MW, Kim BS, Kang YK. : Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. <i>Gastric Cancer.</i> 2015 Dec 11. [Epub ahead of print]
Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, <b>Park SR</b> , Shinozaki K, Takano T, Kang YK; SOS study investigators. : Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase 3 trial (SOS). <i>Ann Oncol.</i> 2015 Oct;26(10):2097-101.

Lee MK, Lee WJ, Do YR, Lee KS, Jung KH, Heo DS, Kim SY, Park SY, Jeong HS, Kang JH, Kim SY, <b>Park SR</b> , Yun YH. Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study. <i>Palliat Support Care</i> . 2015 Aug;13(4):1103-11
Park YS, Na YS, Ryu MH, Lee CW, Park HJ, Lee JK, <b>Park SR</b> , Ryoo BY, Kang YK. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. <i>Am J Clin Pathol</i> 2015 Jun;143(6):865-72
Park JH, Ryu MH, Park YS, <b>Park SR</b> , Na YS, Rhoo BY, Kang YK. Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression. <i>BMC Cancer</i> . 2015 Mar 13;15:119.
Oh DY, Doi T, Shirao K, Lee KW, <b>Park SR</b> , Chen Y, Yang L, Valota O, Bang YJ. Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. <i>Cancer Res Treat</i> . 2015 Oct;47(4):687-96
Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, <b>Park SR</b> , Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. <i>Eur J Cancer</i> . 2015 Mar;51(4):482-8
Yoo C, Ryu MH, Park YS, Yoo MW, <b>Park SR</b> , Ryoo BY, Jang SJ, Yook JH, Kim BS, Kang YK. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence. <i>Ann Surg Oncol</i> . 2015 Sep;22(9):2940-7
Noh SH, <b>Park SR</b> , Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncol</i> . 2014 Nov;15(12):1389-96
Park I, Kim YH, Yoon DH, <b>Park SR</b> , Kim HR, Kim JH, Jung HY, Lee GH, Cho KJ, Kim SB. Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience. <i>Cancer Chemother Pharmacol</i> . 2014 Nov;74(5):995-1003.
Yoo C, Ryu MH, Na YS, Ryoo BY, <b>Park SR</b> , Kang YK. : Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. <i>Ann Oncol</i> . 2014 Nov;25(11):2272-7
Jeong W, <b>Park SR</b> , Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. <i>Invest New Drugs</i> . 2014 Apr;32(2):340-6
Woo JW, Ryu KW, Park JY, Eom BW, Kim MJ, Yoon HM, <b>Park SR</b> , Kook MC, Choi IJ, Kim YW, Park YI. Prognostic Impact of Microscopic Tumor Involved Resection Margin in Advanced Gastric Cancer Patients after Gastric Resection. <i>World J Surg</i> . 2014 Feb;38(2):439-46
Kim CG, Choi IJ, Lee JY, Cho SJ, Kim SJ, Kim MJ, <b>Park SR</b> , Park YL. Outcomes of second self-expandable metallic stent insertion for malignant gastric outlet obstruction. <i>Surg Endosc</i> . 2014 Jan;28(1):281-8
Jeong W, Rapisarda A, <b>Park SR</b> , Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1 $\alpha$ ), in patients with refractory solid tumors. <i>Cancer Chemother Pharmacol</i> . 2014 Feb;73(2):343-8.

Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, <b>Park SR</b> , Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncol</i> . 2013 Nov;14(12):e535-47
Lee MK, Baek SK, Kim SY, Heo DS, Yun YH, <b>Park SR</b> , Kim JS. Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: A prospective cohort study. <i>Palliat Med</i> . 2013 Feb;27(2):144-54.
Kim SY, Chang YJ, Do YR, Kim SY, Park SY, Jeong HS, Kang JH, Kim SY, Ro JS, Lee JL, Lee WJ, <b>Park SR</b> , Yun YH. Employment Status and Work-Related Difficulties among Family Members of Terminally Ill Patients Compared with the General Population. <i>Asian Pac J Cancer Prev</i> . 2013;14(1):373-80.
Chang YJ, Kwon YC, Lee WJ, Do YR, Seok LK, Kim HT, <b>Park SR</b> , Hong YS, Chung IJ, Yun YH. Burdens, needs and satisfaction of terminal cancer patients and their caregivers. <i>Asian Pac J Cancer Prev</i> 2013;14:209-16.
Roy AC, <b>Park SR</b> , Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Ann Oncol</i> . 2013 Jun;24(6):1567-73
Yun YH, Lee MK, Park SM, Kim YA, Lee WJ, Lee KS, Choi JS, Jung KH, Do YR, Kim SY, Heo DS, Kim HT, <b>Park SR</b> . Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: a prospective cohort study. <i>Ann Oncol</i> . 2013 Feb;24(2):489-94.
Jung SJ, Cho SJ, Choi IJ, Kook MC, Kim CG, Lee JY, <b>Park SR</b> , Lee JH, Ryu KW, Kim YW. Argon plasma coagulation is safe and effective for treating smaller gastric lesions with low-grade dysplasia: a comparison with endoscopic submucosal dissection. <i>Surg Endosc</i> . 2013 Apr;27(4):1211-8.
Kang YK, Kang BW, Im SA, Lee JL, <b>Park SR</b> , Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation. <i>Cancer Chemother Pharmacol</i> . 2013 Jan;71(1):43-51
Kim TH, <b>Park SR</b> , Ryu KW, Kim YW, Bae JM, Lee JH, Choi IJ, Kim YJ, Kim DY. Phase 3 Trial of Postoperative Chemotherapy Alone Versus Chemoradiation Therapy in Stage III-IV Gastric Cancer Treated With R0 Gastrectomy and D2 Lymph Node Dissection. <i>Int J Radiat Oncol Biol Phys</i> . 2012 Dec 1;84(5):e585-92.
Lee SE, Lee JH, Ryu KW, Nam BH, Cho SJ, Lee JY, Kim CG, Choi IJ, Kook MC, <b>Park SR</b> , Kim YW. Preoperative plasma fibrinogen level is a useful predictor of adjacent organ involvement in patients with advanced gastric cancer. <i>J Gastric Cancer</i> 2012;12:81-7.
Kim CG, <b>Park SR</b> , Choi IJ, Lee JY, Cho SJ, Park YI, Nam BH, Kim YW. Effect of chemotherapy on the outcome of self-expandable metallic stents in gastric cancer patients with malignant outlet obstruction. <i>Endoscopy</i> . 2012;44:807-12.
Lee SE, Lee JH, Ryu KW, Nam B, Kim CG, <b>Park SR</b> , Kook MC, Kim YW. Changing pattern of postoperative body weight and its association with recurrence and survival after curative resection for gastric cancer. <i>Hepatogastroenterology</i> . 2012;59(114):430-5
Han MA, Oh MG, Choi IJ, <b>Park SR</b> , Ryu KW, Nam BH, Cho SJ, Kim CG, Lee JH, Kim YW. Association of family history with cancer recurrence and survival in patients with gastric cancer. <i>J Clin Oncol</i> . 2012 1;30(7):701-8.

<p>Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, <b>Park SR</b>, Kang BY, Kang YK. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. <i>Invest New Drugs</i>. 2012 Dec;30(6):2377-83</p>
<p>Yoon HM, Ryu KW, Nam BH, Cho SJ, <b>Park SR</b>, Lee JY, Lee JH, Kook MC, Choi IJ, Kim YW. Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer? <i>J Am Coll Surg</i>. 2012;214(1):88-96.</p>
<p>Eom BW, Yoon HM, Ryu KW, Lee JH, Cho SJ, Lee JY, Kim CG, Choi IJ, Lee JS, Kook MC, Rhee JY, <b>Park SR</b>, Kim YW. Comparison of surgical performance and short-term clinical outcomes between laparoscopic and robotic surgery in distal gastric cancer. <i>Eur J Surg Oncol</i>. 2012;38(1):57-63.</p>
<p>Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, <b>Park SR</b>, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. <i>J Clin Oncol</i>. 2011 20;29(30):3968-76.</p>
<p>Yun YH, Lee MK, Kim SY, Lee WJ, Jung KH, Do YR, Kim S, Heo DS, Choi JS, Park SY, Jeong HS, Kang JH, Kim SY, Ro J, Lee JL, <b>Park SR</b>, Park S. Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. <i>J Clin Oncol</i>. 2011; 20;29(18):2474-80.</p>
<p>Nam JH, Choi IJ, Cho SJ, Kim CG, Lee JY, Nam SY, <b>Park SR</b>, Kook MC, Nam BH, Kim YW. Helicobacter pylori infection and histological changes in siblings of young gastric cancer patients. <i>J Gastroenterol Hepatol</i>. 2011;26(7):1157-63.</p>
<p>Kim YW, <b>Park SR</b>, Lee JS. Role of Preoperative Clinical Staging with Abdominal Computed Tomography in the Era of Preoperative Treatment. <i>Ann Surg</i>. 2011 Feb 25. [Epub ahead of print]</p>
<p>Cho SJ, Choi IJ, Kim CG, Lee JY, Kook MC, Seong MW, <b>Park SR</b>, Lee JS, Kim YW, Ryu KW, Lee JH, Nam BH, Park YI. Helicobacter pylori Seropositivity Is Associated with Gastric Cancer Regardless of Tumor Subtype in Korea. <i>Gut Liver</i>. 2010;4(4):466-74.</p>
<p>Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, Chiku S, Kuchiba A, Lee YS, Yoon KA, Kook MC, <b>Park SR</b>, Kim YW, Tanaka H, Tajima K, Hirose H, Tanioka F, Matsuno Y, Sugimura H, Kato S, Nakamura T, Nishina T, Yasui W, Aoyagi K, Sasaki H, Yanagihara K, Katai H, Shimoda T, Yoshida T, Nakamura Y, Hirohashi S, Sakamoto H. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. <i>Gastroenterology</i>. 2011;140(3):892-902.</p>
<p>Eom BW, Ryu KW, Lee JH, Choi IJ, Kook MC, Cho SJ, Lee JY, Kim CG, <b>Park SR</b>, Lee JS, Kim YW. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. <i>Ann Surg Oncol</i>. 2011;18(2):358-64.</p>
<p>Kim J, Choi IJ, Kim CG, Lee JY, Cho SJ, <b>Park SR</b>, Lee JH, Ryu KW, Kim YW, Park YI. Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer. <i>Surg Endosc</i>. 2011;25(5):1505-13.</p>
<p>Cho SJ, Choi IJ, Kim CG, Lee JY, Kook MC, Seong MW, <b>Park SR</b>, Lee JS, Kim YW, Ryu KW, Lee JH, Nam BH, Park YI. Helicobacter pylori Seropositivity Is Associated with Gastric Cancer Regardless of Tumor Subtype in Korea. <i>Gut Liver</i>. 2010;4(4):466-74.</p>



Eom BW, Yoon H, Ryu KW, Lee JH, Cho SJ, Lee JY, Kim CG, Choi IJ, Lee JS, Kook MC, <b>Park SR</b> , Nam BH, Kim YW. Predictors of timing and patterns of recurrence after curative resection for gastric cancer. <i>Dig Surg</i> . 2010;27(6):481-6.
Kim CG, Choi IJ, Lee JY, Cho SJ, <b>Park SR</b> , Lee JH, Ryu KW, Kim YW, Park YI. Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study. <i>Gastrointest Endosc</i> . 2010;72(1):25-32.
Lee JH, Ryu KW, Lee SE, Cho SJ, Lee JY, Kim CG, Choi IJ, Kook MC, Kim MJ, <b>Park SR</b> , Lee JS, Nam BH, Kim YW. Learning Curve for Identification of Sentinel Lymph Node Based on a Cumulative Sum Analysis in Gastric Cancer. <i>Dig Surg</i> . 2009;26(6): 465-470
Han SW, Oh DY, Im SA, <b>Park SR</b> , Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. <i>Cancer Sci</i> . 2010;101(3):793-9.
Lee SE, Ryu KW, Nam BH, Lee JH, Choi IJ, Kook MC, <b>Park SR</b> , Kim YW. Prognostic significance of intraoperatively estimated surgical stage in curatively resected gastric cancer patients. <i>J Am Coll Surg</i> 2009;209:461-7
Lee SE, Ryu KW, Nam BH, Lee JH, Kim YW, Yu JS, Cho SJ, Lee JY, Kim CG, Choi IJ, Kook MC, <b>Park SR</b> , Kim MJ, Lee JS. Technical feasibility and safety of laparoscopy-assisted total gastrectomy in gastric cancer: a comparative study with laparoscopy-assisted distal gastrectomy. <i>J Surg Oncol</i> 2009;100:392-5
Lee SE, Kim YW, Lee JH, Ryu KW, Cho SJ, Lee JY, Kim CG, Choi IJ, Kook MC, Nam BH, <b>Park SR</b> , Kim MJ, Lee JS. Developing an institutional protocol guideline for laparoscopy-assisted distal gastrectomy. <i>Ann Surg Oncol</i> 2009;16:2231-6
Nam SY, Choi IJ, Park KW, Kim CG, Lee JY, Kook MC, Lee JS, <b>Park SR</b> , Lee JH, Ryu KW, Kim YW. Effect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees. <i>Eur J Gastroenterol Hepatol</i> 2009;21:855-60
Lee SE, Lee JH, Ryu KW, Cho SJ, Lee JY, Kim CG, Choi IJ, Kook MC, Nam BH, <b>Park SR</b> , Lee JS, Kim YW. Sentinel node mapping and skip metastases in patients with early gastric cancer. <i>Ann Surg Oncol</i> 2009;16:603-8
Han SW, Oh DY, Im SA, <b>Park SR</b> , Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. <i>Br J Cancer</i> 2009;100:298-304
Lee JH, Ryu KW, Nam BH, Kook MC, Cho SJ, Lee JY, Kim CG, Choi IJ, <b>Park SR</b> , Kim YW. Factors associated with detection failure and false-negative sentinel node biopsy findings in gastric cancer: results of prospective single center trials. <i>J Surg Oncol</i> 2009;99:137-42
Kim CG, Choi IJ, Lee JY, Cho SJ, Lee JH, Ryu KW, <b>Park SR</b> , Bae JM, Kim YW. Effective diameter of balloon dilation for benign esophagojejunal anastomotic stricture after total gastrectomy. <i>Surg Endosc</i> 2009;23:1775-80
Lee SE, Lee JH, Kook MC, Yoo JS, Ryu KW, Lee JS, Lee JY, Kim CG, Choi IJ, <b>Park SR</b> , Kim YW. T2 or greater disease but were diagnosed preoperatively with early gastric cancer. <i>Hepatogastroenterol</i> 2008;55:2282-6

Lee JH, Ryu KW, Kook MC, Lee JY, Kim CG, Choi IJ, Kim SK, Jang S, <b>Park SR</b> , Kim YW, Nam BH, Bae JM. Feasibility of laparoscopic sentinel basin dissection for limited resection in early gastric cancer. J Surg Oncol 2008 Oct 1;98(5):331-5
Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, <b>Park SR</b> , Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008;99:584-90
Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, Matsuda N, Nakamura T, Hyodo I, Nishina T, Yasui W, Hirose H, Hayashi M, Toshiro E, Ohnami S, Sekine A, Sato Y, Totsuka H, Ando M, Takemura R, Takahashi Y, Ohdaira M, Aoki K, Honmyo I, Chiku S, Aoyagi K, Sasaki H, Ohnami S, Yanagihara K, Yoon KA, Kook MC, Lee YS, <b>Park SR</b> , Kim CG, Choi IJ, Yoshida T, Nakamura Y, Hirohashi S. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40(6):730-40.
Kim YH, Chung HC, Kang WK, <b>Park SR</b> , Kim CS, Kim TY, Shin SW, Park BJ, Cha SJ, Bang YJ. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemother Pharmacol 2008 ;62(2):263-70
Lee JH, Paik YH, Lee JS, Ryu KW, Kim CG, <b>Park SR</b> , Kim YW, Kook MC, Nam BH, Bae JM. Abdominal Shape of Gastric Cancer Patients Influences Short-Term Surgical Outcomes. Ann Surg Oncol 2007;14:1288-94
Lee JH, Ryu KW, Lee JS, Lee JR, Kim CG, Choi IJ, <b>Park SR</b> , Kook MC, Kim YW, Bae JM. Decisions for extent of gastric surgery in gastric cancer patients: Younger patients require more attention than the elderly. J Surg Oncol. 2007;95:485-90
Lee JH, Paik YH, Lee JS, Song HJ, Ryu KW, Kim CG, <b>Park SR</b> , Kook MC, Kim YW, Bae JM. Candidates for Curative Resection in Advanced Gastric Cancer Patients Who Had Equivocal Para-aortic Lymph Node Metastasis on Computed Tomographic Scan. Ann Surg Oncol 2006;13:1163-1167
Lee JH, Ryu KW, Lee JH, <b>Park SR</b> , Kim CG, Kook MC, Nam BH, Kim YW, Bae JM. Learning curve for total gastrectomy with d2 lymph node dissection: cumulative sum analysis for qualified surgery. Ann Surg Oncol 2006;13:1175-1181
Lee JH, Bae JS, Ryu KW, Lee JS, <b>Park SR</b> , Kim CG, Kook MC, Choi IJ, Kim YW, Park JG, Bae JM. Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol. 2006;12(16):2588-92
Chun JH, Kim HK, Lee JS, Choi JY, Hwangbo B, Lee HG, <b>Park SR</b> , Choi IJ, Kim CG, Ryu KW, Kim YW, Lee JS, Bae JM. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005;28:188-194
Choi IS, Oh DY, Kwon JH, Kim SI, <b>Park SR</b> , Bak JY, Kim JH, Kim DW, Kim YT, Kim TY, You CK, Kim YW, Heo DS, Bang YJ, Sung SW, Park CI, Kim NK. Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. Jpn J Clin Oncol 2005;35:6-12
Baek JY, <b>Park SR</b> , Choi IS, Kim SI, Kim DW, Kim JH, Yoon SS, Park S, Kim BK, Kim NK, Heo DS. Angioimmunoblastic T-cell lymphoma: Clinical characteristics and treatment outcomes. Korean J Hematol 2005;40:8-14

Kim DY, Lee KW, Yun T, **Park SR**, Jung JY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. *Jpn J Clin Oncol* 2003;33:608-612

Choi IS, Kim BS, **Park SR**, Lee SY, Kim do Y, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. *Lung Cancer* 2003;39:99-101

Bang SM, **Park SR**, Park SH, Cho EK, Yoon SS, Shin DB, Lee JH, Park S, Kim BK, Kim NK. Clinical features of Waldenstrom macroglobulinemia in Korea. *Korean J Intern Med* 2004;19:137-140

Kim JS, Baek JY, **Park SR**, Choi IS, Kim SI, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients. *Cancer Res and Treatment* 2004;36:372-376

### Book chapter

암진료 가이드: 암 환자 돌봄과 완화 요법	일조각	2005
위암 100 문 100 답	국립암센터	2010
종양학	일조각	2012
제 3 판 환자를 위한 위장관기질종양 치료지침서	범문에듀케이션	2014
Multidisciplinary Management of Gastrointestinal Cancers: Gastric Cancer Management: East vs. West?	World Scientific Publishing	2015

### GCP Training

Period	Title
24 Oct 2012	The Collaborative Institutional Training Initiative (CITI)_Basic Course
25 Oct 2012	The Collaborative Institutional Training Initiative (CITI)_Advanced One
02 Dec 2012	The Collaborative Institutional Training Initiative (CITI)_GCP Group
29 Sep 2014	Korea Centers for Disease Control & Prevention - Clinical Research and Ethics

### Clinical Trials Involved

Year	Phase	GC		HCC		GIST	
		SIT	IIT	SIT	IIT	SIT	IIT
2013	Phase I	1	1	3			
	Phase II	2	0	1			
	Phase III	4	2	2			
	Phase IV/기타					1	3

2014	Phase I	5		2			
	Phase II	1		4			
	Phase III	2	1				
	Phase IV/7 E}		1	1			2
2015	Phase I	2		5			
	Phase II	3		3			
	Phase III	4		1			
	Phase IV/7 E}						